Different versions of the anatomical therapeutic chemical classification system and the defined daily dose--are drug utilisation data comparable?
about
DRUG-DRUG INTERACTION PROFILES OF MEDICATION REGIMENS EXTRACTED FROM A DE-IDENTIFIED ELECTRONIC MEDICAL RECORDS SYSTEMProblems in collecting comparable national drug use data in Europe: the example of antibacterials.European surveillance of antimicrobial consumption (ESAC): data collection performance and methodological approach.Can authorities appreciably enhance the prescribing of oral generic risperidone to conserve resources? Findings from across Europe and their implications.Different initiatives across Europe to enhance losartan utilization post generics: impact and implications.Perioperative antibiotic prophylaxis in elective surgeries in IranPrescribing efficiency of proton pump inhibitors in China: influence and future directionsThe impact of obesity on drug prescribing in primary carePolicies to enhance prescribing efficiency in europe: findings and future implications.The relationship between target-class and the physicochemical properties of antibacterial drugs.Measurement of antibiotic consumption: A practical guide to the use of the Anatomical Thgerapeutic Chemical classification and Definied Daily Dose system methodology in CanadaAccounting for the sedative and analgesic effects of medication changes during patient participation in clinical research studies: measurement development and application to a sample of institutionalized geriatric patients.Application of ATC/DDD methodology to evaluate of antibiotic use in a general hospital in Turkey.Combination of prescribing restrictions and policies to engineer low prices to reduce reimbursement costs.Influence of multiple initiatives in Sweden to enhance ARB prescribing efficiency following generic losartan; findings and implications for other countries.Reforms and initiatives in Scotland in recent years to encourage the prescribing of generic drugs, their influence and implications for other countries.Impact of delisting ARBs, apart from losartan, on ARB utilisation patterns in Denmark: implications for other countries.Possible ways to enhance renin-angiotensin prescribing efficiency: Republic of Serbia as a case history?Review of ongoing initiatives to improve prescribing efficiency in China; angiotensin receptor blockers as a case history.Initiatives to improve prescribing efficiency for drugs to treat Parkinson's disease in Croatia: influence and future directions.Risk factors for venous thromboembolic events in cancer patients.Salivary secretion and drug treatment in four 70-year-old Swedish cohorts during a period of 30 years.Epithelial-Mesenchymal Transition Phenotype, Metformin, and Survival for Colorectal Cancer Patients with Diabetes Mellitus II.Changes in the utilization of venlafaxine after the introduction of generics in Sweden.Generic atypical antipsychotic drugs in Belgium: their influence and implications.Imperative to consider multiple initiatives to maximize prescribing efficiency from generic availability: case history from Abu DhabiThe Use of the World Health Organisation Anatomical Therapeutic Chemical/Defined Daily Dose Methodology in Canada
P2860
Q28828695-A3BD6224-BE33-4546-A6C5-174574920DA7Q30786327-93F029AD-970B-4291-9435-8A5446AA0E79Q30960100-7F9DA4DC-C60B-4F82-BB95-B2696A6CA687Q33816182-A30CD026-03DA-4D33-97F0-EB4935BE4407Q34304782-ED6586C1-1B2B-40DD-9415-77E6F23F8610Q34451108-C8900228-0131-4980-80BC-AC4589411685Q35021173-0449AF5E-07D9-4423-ADF7-8C3643E28A59Q35021250-74E770A9-FE19-4929-BF22-75A5BB345E84Q35155250-97D3EFD8-1DA0-40B3-9FA0-99A1F11289F7Q35955567-40953057-5DD8-4735-AE72-7C78884130B3Q36170724-13AFF16A-ED07-4844-B85D-E3D389AAF063Q36593584-D4420D18-DEF0-4ED7-AC4F-69C7E613D023Q37356726-CF0210D9-3B0E-4EE3-B5A4-B71A692EF294Q37847158-29F2B2D1-8CB8-4AB8-9AF4-A0A54B3D3CEFQ38096468-7045A5CB-1680-46A5-AB0C-2B0D14FE4954Q38131544-4F127123-FC88-40E2-90E5-C14F7E10C547Q38150706-872B1BCC-BB97-49D9-81F4-46A613BA97BAQ38162867-BDA6A78B-ECAA-4719-AEF8-EFD5F58F9A07Q38263092-4F82DD8E-C66B-4428-ACE8-D03967DF9FABQ39583380-42127DE3-80F1-4C8D-89FE-223A26F0AB43Q40494174-F1A0F23E-B469-4CA0-9D5A-E4329BAFF095Q40627246-A4CB7CE4-C72F-40C5-81F7-3632AFB59A0AQ40989059-23FDEA9F-528B-4162-85FA-0889ED78EADBQ44560607-28C435CD-B20E-4D41-B5AF-71182C9BF332Q45809881-F0BA136C-7D2E-47F2-8719-A1A07124C605Q56828549-A5C0B8EE-03A5-443D-8487-CFB0FE126AA4Q59157766-6E1FE0B5-F97F-4B4B-B975-49B1FD2DDB7E
P2860
Different versions of the anatomical therapeutic chemical classification system and the defined daily dose--are drug utilisation data comparable?
description
2000 nî lūn-bûn
@nan
2000 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Different versions of the anat ...... g utilisation data comparable?
@ast
Different versions of the anat ...... g utilisation data comparable?
@en
type
label
Different versions of the anat ...... g utilisation data comparable?
@ast
Different versions of the anat ...... g utilisation data comparable?
@en
prefLabel
Different versions of the anat ...... g utilisation data comparable?
@ast
Different versions of the anat ...... g utilisation data comparable?
@en
P2093
P356
P1476
Different versions of the anat ...... g utilisation data comparable?
@en
P2093
P2888
P304
P356
10.1007/S002280000200
P577
2000-12-01T00:00:00Z
P6179
1006448919